| Identification | Back Directory | [Name]
2-Pyrrolidinone, 1-[(4-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)-1-piperidinyl]-, (3R)- | [CAS]
1801151-15-4 | [Synonyms]
BMT108908
BMT-108908
BMT 108908
2-Pyrrolidinone, 1-[(4-fluorophenyl)methyl]-3-[4-(4-hydroxyphenyl)-1-piperidinyl]-, (3R)- | [Molecular Formula]
C22H25FN2O2 | [MOL File]
1801151-15-4.mol | [Molecular Weight]
368.44 |
| Hazard Information | Back Directory | [Description]
BMT-108908 is a Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains. BMT-108908 displayed potent rat GluN2B binding adjunctive therapy for TRD has demonstrated a 60% response rate, with 78% of responders having maintained a response for at least 1 week. | [Uses]
BMT-108908 is a negative allosteric modulator with selective activity on the NR2B subtype of the NMDA receptor. BMT-108908 has been shown to damage cognition in research, affecting cognitive functions in multiple areas. BMT-108908 failed to show a significant impact on the γ wave power of the EEG in the experiment, but it had a significant inhibitory and enhancement effect on the β wave and δ wave power[1]. | [References]
[1] The qEEG Signature of Selective NMDA NR2B Negative Allosteric Modulators; A Potential Translational Biomarker for Drug Development DOI:10.1371/journal.pone.0152729 |
|
|